A case of pretibial myxedema treated with teprotumumab

Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion

“…A similar mechanism may effect thyroid dermopathy; several previous reports demonstrate response of dermopathy to IGF-1R inhibition. 5 , 6 , 7 , 8 Our patient had preexisting peripheral edema diagnosed as a component of Hashimoto thyroiditis which severely worsened during the Graves episode. While the characterization of this worsening edema is incomplete in the absence of formal dermatologic and radiographic evaluation, photographic documentation is presented.…”

“…Case reports have demonstrated response of thyroid dermopathy to the standardized dosing regimen. 5 , 6 , 7 , 8 We present a case of rapid improvement in symptoms of TED and amelioration of worsening peripheral edema and acropathy (not to be confused with acropachy) after treatment with teprotumumab.…”

Tofacitinib Treatment for Pretibial Myxedema

“…Topical and intralesional steroids may be beneficial for mild PTM but are not consistently successful in preventing PTM progression . Case reports and series have shown that teprotumumab, an inhibitor of the insulinlike growth factor 1 receptor, is effective in improving PTM . However, teprotumumab has high cost and low availability in some countries, including China; thus, economical and effective treatments are still needed.…”

Teprotumumab as a novel treatment for pretibial myxoedema

“…Octreotide, a somatostatin analogue with partial IGF‐1 antagonist properties, has previously demonstrated some efficacy for both TED and PTM 5 . Moreover, two recent case reports have shown improvement in PTM after teprotumumab infusions 6,7 . We retrospectively assessed response to treatment in a cohort of patients with PTM who received teprotumumab for TED.…”